Zacks: Brokerages Expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Will Post Earnings of $0.05 Per Share

Brokerages expect that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will announce earnings of $0.05 per share for the current quarter, Zacks reports. Three analysts have made estimates for Amphastar Pharmaceuticals’ earnings, with estimates ranging from ($0.02) to $0.12. Amphastar Pharmaceuticals posted earnings of $0.13 per share during the same quarter last year, which indicates a negative year over year growth rate of 61.5%. The firm is expected to issue its next quarterly earnings results on Tuesday, March 10th.

On average, analysts expect that Amphastar Pharmaceuticals will report full year earnings of $0.31 per share for the current financial year, with EPS estimates ranging from $0.27 to $0.33. For the next year, analysts forecast that the firm will report earnings of $0.54 per share, with EPS estimates ranging from $0.36 to $0.64. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, November 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. Amphastar Pharmaceuticals had a return on equity of 5.07% and a net margin of 15.77%. The firm had revenue of $80.14 million during the quarter, compared to analysts’ expectations of $78.53 million. During the same quarter in the prior year, the business earned $0.12 earnings per share. The company’s revenue was up 6.1% on a year-over-year basis.

A number of equities research analysts have issued reports on the company. ValuEngine lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 20th. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. Finally, TheStreet downgraded shares of Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $24.05.

In related news, Director Richard K. Prins sold 3,882 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $22.58, for a total transaction of $87,655.56. Following the transaction, the director now directly owns 43,191 shares of the company’s stock, valued at $975,252.78. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jack Y. Zhang sold 300,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $20.82, for a total transaction of $6,246,000.00. Following the transaction, the chief executive officer now directly owns 2,147,316 shares in the company, valued at $44,707,119.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 334,537 shares of company stock worth $6,999,921. 30.80% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. lifted its position in Amphastar Pharmaceuticals by 1.4% during the second quarter. Prudential Financial Inc. now owns 63,076 shares of the company’s stock valued at $1,331,000 after purchasing an additional 870 shares during the period. JPMorgan Chase & Co. increased its holdings in Amphastar Pharmaceuticals by 15.4% in the second quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock valued at $205,000 after buying an additional 1,314 shares in the last quarter. Rhumbline Advisers increased its holdings in Amphastar Pharmaceuticals by 1.3% in the third quarter. Rhumbline Advisers now owns 108,931 shares of the company’s stock valued at $2,160,000 after buying an additional 1,358 shares in the last quarter. Swiss National Bank increased its holdings in Amphastar Pharmaceuticals by 2.2% in the second quarter. Swiss National Bank now owns 64,400 shares of the company’s stock valued at $1,359,000 after buying an additional 1,400 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in Amphastar Pharmaceuticals by 2.7% in the second quarter. Arizona State Retirement System now owns 54,756 shares of the company’s stock valued at $1,156,000 after buying an additional 1,422 shares in the last quarter. 47.20% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:AMPH traded up $0.15 during trading on Friday, hitting $17.22. 172,800 shares of the company’s stock traded hands, compared to its average volume of 220,272. The company has a 50-day moving average price of $19.53 and a 200-day moving average price of $20.56. The company has a market cap of $801.23 million, a price-to-earnings ratio of 82.00 and a beta of 1.17. The company has a current ratio of 3.11, a quick ratio of 1.83 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a 52 week low of $16.71 and a 52 week high of $25.43.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Recommended Story: What is a good rate of return for a mutual fund?

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.